Dual Inhibition of FLT3 and AXL by Gilteritinib Overcomes Hematopoietic Niche-Driven Resistance Mechanisms in FLT3-ITD Acute Myeloid Leukemia

Dumas, P., Villacreces, A., Guitart, A. V., El-habhab, A., Massara, L., Mansier, O., Bidet, A., Martineau, D., Fernandez, S., Leguay, T., Pigneux, A., Vigon, I., Pasquet, J. and Desplat, V. Dual Inhibition of FLT3 and AXL by Gilteritinib Overcomes Hematopoietic Niche-Driven Resistance Mechanisms in FLT3-ITD Acute Myeloid Leukemia.  Clinical Cancer Research. 2021; 27:6012-25. doi: 10.1158/1078-0432.ccr-20-3114